India is expected to provide 700M doses of Covaxin in 2021

Covaxin Phase III trial is anticipated by March 2021

India is expected to provide 700M doses of Covaxin in 2021. Source: pexels.com

According to GlobalData, an emergency approval for Covaxin in India will further strengthen its confidence. It will also confirm Bharat Biotech’s commitment to making the locally produced vaccine popular in other parts of the world.

Bharat Biotech recently applied for regulatory approval to conduct clinical trials in Bangladesh and applied for a EUA in the Philippines. Also, it has partnered with Brazilian company Precisa Medicamentos to distribute 12 million doses of Covaxin.

Brazil had 9,524,640 confirmed cases as of February 8, 2021, the third-highest number of confirmed cases in the world. Bangladesh had 538,378 confirmed cases and the Philippines have 538,995.

According to data, India aims to supply COVID-19 vaccines to friendly countries such as Mauritius, the Philippines, and Myanmar. Overall, 0.81 million doses of Covaxin will be provided free of cost as a goodwill gesture.

We’ve reported that Moderna on track to deliver additional 100 million doses to the US.

SEE ALSO:

• COVID-19 vaccine frontrunners: who are they (UPD)
• Store closures and charity: H&M, Pull & Bear, Bershka amid pandemic
• COVID-19 insurance types: everything you should know